Moderna, Inc. Variable Lease, Cost
Moderna, Inc. (MRNA) reported Variable Lease, Cost of $22.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-20
- Moderna, Inc. variable lease, cost for the quarter ending 2020-12-31 was $1.38M, a 52.88% increase year-over-year.
- Moderna, Inc. variable lease, cost for the quarter ending 2020-09-30 was $1.12M, a 21.68% decline year-over-year.
- Moderna, Inc. variable lease, cost for the quarter ending 2020-06-30 was $1.09M, a 6.83% decline year-over-year.
- Moderna, Inc. variable lease, cost for the quarter ending 2020-03-31 was $1.41M, a 57.38% increase year-over-year.
- Moderna, Inc. variable lease, cost for fiscal 2025 was $22.00M, a 47.62% decline from fiscal 2024.
- Moderna, Inc. variable lease, cost for fiscal 2024 was $42.00M, a 62.83% decline from fiscal 2023.
- Moderna, Inc. variable lease, cost for fiscal 2023 was $113.00M, a 31.52% decline from fiscal 2022.
- Moderna, Inc. variable lease, cost for fiscal 2022 was $165.00M, a 65.00% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $22.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $42.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $113.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $165.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $100.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $2.50M derived: sum of 2 quarters · filed 2023-02-24 | $3.59M derived: sum of 3 quarters · filed 2023-02-24 | $5.00M 10-K · filed 2023-02-24 | $5.23M 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.12M 10-Q · filed 2020-10-30 | $2.21M derived: sum of 2 quarters · filed 2020-10-30 | $3.62M 10-Q · filed 2020-10-30 | $4.52M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $1.09M 10-Q · filed 2020-08-06 | $2.50M 10-Q · filed 2020-08-06 | $3.40M derived: sum of 3 quarters · filed 2021-02-26 | $4.83M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $1.41M 10-Q · filed 2020-05-07 | $2.31M derived: sum of 2 quarters · filed 2021-02-26 | $3.74M derived: sum of 3 quarters · filed 2021-02-26 | $4.91M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.33M derived: sum of 2 quarters · filed 2021-02-26 | $3.50M derived: sum of 3 quarters · filed 2021-02-26 | $4.40M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $1.43M 10-Q · filed 2020-10-30 | $2.60M derived: sum of 2 quarters · filed 2020-10-30 | $3.50M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $1.17M 10-Q · filed 2020-08-06 | $2.06M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $894.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |